Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 16Uterine Cervical Neoplasms 8Melanoma 7Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Breast Neoplasms 5Recurrence 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Surveys and Questionnaires 23Radiotherapy 22Letrozole 22Doxorubicin 21Megestrol Acetate 20olaparib 19lenvatinib 19Taxes 17Specimen Handling 17Docetaxel 17Nivolumab 16Magnetic Resonance Spectroscopy 16dostarlimab 15Metformin 15Blood Specimen Collection 14Observation 13Gemcitabine 13Biopsy 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11temsirolimus 10abemaciclib 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Interleukin-2 × Gynecologic × Clear all
NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Alaunos Therapeutics

Phase 1/2 Terminated
8 enrolled 12 charts
GastrointestinalGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡